Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Olaszország2. fázis

Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial)

A legfontosabb adatok

Ki végzi
Azienda Ospedaliera Universitaria Integrata Verona
Hol
Padova és Verona (Olaszország)Mind a 2 helyszín megnézése
Állapot
Toborzás még nem indult
Fázis
2. fázis
Résztvevők
150 fő, tervezett
Kezdés
2026. szept. 30.
Várható befejezés
2028. szept. 30.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. augusztus 14.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for men aged 50 or older and post-menopausal women with osteoporosis and erosive hand osteoarthritis. They must never have had osteoporosis medicine and must be able to start denosumab or zoledronic acid.

Életkor
Men ≥50 years; post-menopausal women (record minimum age 18 Years)
Nem
Men and post-menopausal women
A betegség stádiuma
Erosive (inflammatory) hand osteoarthritis with past inflammatory flares and current signs of inflammation in the finger joints. At least 1 finger joint must look like a 'J' or 'E' phase joint on X-ray. Osteoporosis must also be present.
Korábbi kezelés
No earlier anti-osteoporosis medicine. No IV bisphosphonates ever, no oral bisphosphonates within 12 months before screening, no denosumab ever, and no other drugs like romosozumab, PTH analogs or SERMs.
Biomarker vagy leletérték
Bone density (BMD) T-score of ≤ -2.5 at the lumbar spine, total hip or femoral neck, or a T-score of ≤-2.0 there plus an existing major osteoporotic (MOF) fracture.

A részvétel fő kizáró okai

  • Cancer within the last 5 years, except some skin cancers or cervical carcinoma in situ
  • Other inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis or gout
  • Past or active jaw bone death (ONJ), active dental infection or unhealed mouth surgery
  • Kidney filtration (eGFR) < 35 mL/minute/1.73 m^2, low blood calcium or vitamin D < 20 ng/mL (<49.9 nmol/L)
  • Past solid organ or bone marrow transplant, or other bone diseases

A regiszter feltételei, szó szerint

Mind a 34 feltétel megnézéseKevesebb

Ki vehet részt

  • Men ≥50 years of age and post-menopausal women with osteoporosis naïve to any anti-osteoporosis medication candidate to treatment to either denosumab of zoledronic acid
  • Subjects with hand OA having suffered from transient inflammatory attacks of the interphalangeal finger joints characteristic for what has been termed ‘inflammatory’ or ‘erosive’ hand OA
  • Subjects with hand OA showing inflammatory signs, either clinically or ultrasonographically, of the interphalangeal finger joints
  • Subjects with hand OA in which at least 1 interphalangeal finger joint has the typical appearance on the X-rays of a ‘J’ or ‘E’ phase joint as defined by the criteria mentioned above
  • Able and willing to give written informed consent and to comply with the requirements of the study protocol
  • A baseline BMD T-score of ≤ -2.5 at the lumbar spine, total hip, or femoral neck or baseline T-score of ≤-2.0 at the lumbar spine, total hip, or femoral neck + a prevalent MOF fracture
  • Signed informed consent for participation in the study and for the processing of personal data

Ki nem vehet részt

  • No past IV bisphosphonates at any time, or any oral bisphosphonate use within 12 months before screening
  • No past treatment with denosumab
  • Recipient of an investigational drug within 4 weeks prior to study drug administration or within 5 half-lives of the investigational drug, whichever is longer
  • No past treatment with other anti-osteoporosis medications (romosozumab, PTH analogs, SERMs etc.)
  • Malignancy within the last 5 years (except cervical carcinoma in situ or basal cell carcinoma or localized squamous cell carcinoma of the skin)
  • Contraindication to, or poorly tolerant of denoosumab therapy (including hypersensitivity to the drug and any excipients)
  • Contraindication to, or poorly tolerant of zoledronic acid therapy (including hypersensitivity to the drug and any excipients)
  • History of atypical femur fracture
  • Unstable systemic medical condition
  • History of Addison disease
  • History of osteomalacia
  • History of osteonecrosis of the jaw (ONJ)
  • History or presence of inflammatory or erosive arthritides other than erosive hand osteoarthritis (EHOA), including rheumatoid arthritis, psoriatic arthritis, crystal-induced arthritis, connective tissue disease-related arthritis, and spondyloarthritis
  • Active osteonecrosis of the jaw (ONJ), unhealed oral surgery, active dental infection, or planned urgent invasive dental procedure that is considered incompatible with safe initiation of study treatment
  • History of anorexia nervosa, bulimia (by history or physical) or obvious malnutrition
  • History of Paget’s disease of bone
  • Other bone diseases which affect bone metabolism
  • History of any solid organ or bone marrow transplant
  • Intolerance to calcium supplements, vitamin D supplements
  • Hypercalcemia >10% above upper limit of normal (ULN)
  • Elevated transaminases or total bilirubin ≥ 2.0 x ULN
  • Hypocalcemia below lower limit of normal (LLN)
  • Estimated glomerular filtration rate < 35 mL/minute/1.73 m^2 at the time of screening/randomization
  • Not a good candidate for study participation in opinion of investigator
  • Uncontrolled hyperthyroidism
  • Uncontrolled hypothyroidism
  • Vitamin D deficiency [25(OH) vitamin D level < 20 ng/mL (<49.9 nmol/L)

Helyszínek itt: Olaszország

  • Azienda Ospedaliera di PadovaPadova, OlaszországToborzás még nem indult
  • Azienda Ospedaliera Universitaria Integrata VeronaVerona, OlaszországToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

To demonstrate the reduction in the progression of erosion volume in the denosumab group vs zoledronic acid group

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. augusztus 14.